Novartis Strengthens American Manufacturing Leadership with Coast-to-Coast U.S. Investment

As part of its $23 billion commitment to expand U.S. manufacturing and research, Novartis is building a connected network of advanced facilities designed to deliver breakthrough medicines closer to patients, and at greater scale. The Carlsbad radioligand therapy site and the flagship North Carolina manufacturing hub illustrate how this investment will enable Novartis’ end-to-end manufacturing of advanced therapies in the U.S. for U.S. patients.

Novartis’ new radioligand therapy sites, including the Carlsbad, California site, expand domestic manufacturing to accelerate the delivery of breakthrough cancer treatments to patients in the U.S.

Novartis opened a new state-of-the-art radioligand therapy (RLT) manufacturing site in Carlsbad, California, marking a major milestone in the company’s broader commitment to discovering, developing and manufacturing medicines in the United States. “As part of our $23 billion commitment to expand our manufacturing and research footprint, we are dedicated now to ensure that all of our key medicines are produced for the United States, in the United States,” said Vas Narasimhan, M.D., Novartis’s CEO.

A form of precision medicine, each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical. “We only have a few days from the moment you start producing to finalizing production to shipping it…to see the impact we have with those treatments on patients is just amazing,” explained Steffen Lang, President of Operations, Novartis.

The Carlsbad location becomes Novartis’s third U.S.-based RLT manufacturing site, building the company’s U.S. footprint to meet future demand while reinforcing leadership in radioligand innovation and infrastructure. Novartis has also announced U.S.-based RLT manufacturing facilities in Winter Park, Florida and Denton, Texas – each built to serve patients across the southern U.S.

While state-of-the-art sites like Carlsbad enable custom-made, time‑sensitive RLT therapies to reach patients in the Western U.S., Alaska and Hawaii, Novartis is simultaneously investing in the foundational manufacturing capacity required to sustain innovation at scale. That long‑term commitment is exemplified by the company’s 700,000-square-foot flagship manufacturing hub in North Carolina, where it broke ground in December.

“Our investments in North Carolina are a core pillar of our $23 billion commitment to U.S.-based infrastructure to support our continued growth in the U.S. market,” said Victor Bultó, Novartis U.S. President. “By building capabilities from active ingredient through final packaging and distribution, we’re strengthening domestic supply, creating jobs, and delivering life‑changing treatments to patients faster while investing meaningfully in the communities where we operate.”

Together these investments form a coast to coast U.S. manufacturing network, creating high-quality jobs and spurring economic growth, while strengthening U.S. leadership in advanced biopharmaceutical manufacturing.

By continuing to invest in U.S.-based innovation and manufacturing, Novartis is bringing life-changing cancer treatments closer to patients, and economic growth to communities.